Ancillary composition for the preparation of committed...

Details Ancillary composition for the preparation of committed... Ancillary composition for the preparation of committed...

2007-08-07

2007-08-07

Ketter, James (Department: 1636)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Method of regulating cell metabolism or physiology

C435S355000, C435S372000

Reexamination Certificate

active

10466186

ABSTRACT:
The invention consists in the use of a maturation agent comprising a mixture of ribosomal and/or membrane fractions for the preparation of mature dendritic cells from immature dendritic cells.

REFERENCES:
patent: 2001/0026937 (2001-10-01), Punnonen et al.
patent: WO 99 47646 (1999-09-01), None
patent: WO 02/074939 (2002-09-01), None
Chakraborty et al. Stimulatory and inhibitory differentiation of human myeloid dendritic cells. Clinical Immunology (Feb. 2000), vol. 94, No. 2, pp. 88-98.
Pascale Jeannin et al., “OmpA Targets Dendritic Cells, Induces Their Maturation and Delivers Antigen into the MHC Class I Presentation Pathway,” Nature Immunology, V. 1, 2000, pp. 502-509.
Haeuw, Jean-Francois et al., “The recombinantKlebsiella pneumoniaeouter membrane protein OmpA has carrier properties for conjugated antigenic peptides”, Eur. J. Biochem. 255, 1998, pp. 446-454.
Nguyen, Thien Ngoc et al., “Chromosomal sequencing using a PCR-based biotin-capture method allowed isolation of the complete gene for the outer membrane protein A ofKlebsiella pneumoniae”, Gene 210, 1998, pp. 93-101.
Jongmans, Wim et al., “Th1-Polarizing Capacity of Clinical-Grade Dendritic Cells is Triggered by Ribomunyl but Is Compromised by PGE2”, J Immunother, vol. 28, No. 5, Sep./Oct. 2005, pp. 480-487.
Peng, Judy C. et al., “Generation and Maturation of Dendritic Cells for Clinical Application Under Serum-Free Conditions”, J Immunother, vol. 28, No. 6, Nov./Dec. 2005, pp. 599-609.
Barrou, Benoit et al., “Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA”, Cancer Immunol. Immunother., 53, 2004, pp. 453-460.
Boyer, Aurelie et al., “Generation of phagocytic MAK and MAC-DC for therapeutic use: Characterization and in vitro functional properties”, Experimental Hematology, 27, 1999, pp. 751-761.
Letters to the Editor, Adoptive Immunotherapy of Ovarian Carcinoma, Gynecologic Oncology, 86, 2002, pp. 102-103.
Salcedo, M. et al., “Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate”, Cancer Immunol. Immunother. , 2005.
Thiounn, Nicolas et al., “Adoptive Immunotherapy for Superficial Bladder Cancer with Autologous Macrophage Activated Killer Cells”, The Journal of Urology, vol. 168, Dec. 2002, pp. 2373-2376.
Salcedo, M. et al., “Preclinical and clinical development of a DC-based melanoma therapeutic vaccine”, Sep. 5-7, 2005, Lisbon, Portugal.
“Characterization of a functional property of MD-APCs according to the invention: Antibody Dependent Cell Cytotoxicity (ADCC) assay”, APC USA 09/194,053, priority EP 96 401 099.5, May 21, 1996.
Coronel, Agnes et al., “Cytokine production and T-cell activation by macrophage-dendritic cells generated for therapeutic use”, British Journal of Haematology, 2001, 114, pp. 671-680.
Tsuji et al::, “Maturation of Human Dendritic Cells by Cell Wall Skeleton of Mycobacterium Bovis Bacillus Calmette-Guerin: Involvement of Toll-Like Receptors”, Infection and Immunity, vol. 68, No. 12, - Dec. 2000, pp. 6883-6890, XP000995248, ***See abstract Materials and Methods, esp. p. 6884, RH column third paragraph, Results, Discussion*** the whole document.
Banchereau and Steinman: “Dentritic Cells and the Control of Immunity” Nature, vol. 392, Mar. 19, 1992, pp. 245-252, XP002134557 ***see whole document, especially ***p. 246, column 2, paragraph 2.
Revillard et al.:, “In Vitro Cell Activating Properties of the Composite Ribosomal Vaccine D53” Mem. Inst. Oswaldo Cruz, vol. 82, No. Suppl. II, 1987, pp. 173-178, XP000995084, Rio de Janeiro *** see whole document, especially *** p. 177, column 2, paragraph 1.
Caux et al.: “Gamma-Interferon Enhances Factor-Dependent Myeloid Proliferation of Human CD34+ Hematopoietic Progenitor Cells” Blood, vol. 79, No. 10, May 15, 1992, pp. 2628-2635, XP002043207, *** see entire document , especially *** p. 2629, column 2, paragraph 2 -p. 2630, column 2, paragraph 1.

Affiliated with

Also associated with

Rating

Ancillary composition for the preparation of committed... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ancillary composition for the preparation of committed..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ancillary composition for the preparation of committed... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3861768